Uniquity Bio Welcomes Will Kane as President and CEO
Mr. Kane joins with more than three decades of biopharmaceutical leadership experience and a track record of building high-performing teams, leading transformational change and delivering exceptional business results across a range of therapeutic areas. He succeeds Brian Lortie, co-founder and former CEO, who stepped down from the company in June 2025. Prior to joining Uniquity Bio, Mr. Kane served as president and chief commercial officer at Anthos Therapeutics, which was recently acquired by Novartis, and he has held senior leadership roles at Karuna Therapeutics, BioXcel Therapeutics, Allergan and Pfizer.
Solrikitug — a highly potent monoclonal antibody targeting Thymic Stromal Lymphopoietin (TSLP), a clinically validated driver of inflammatory response — is advancing through separate Phase II trials in asthma, chronic obstructive pulmonary disease (COPD) and eosinophilic esophagitis (EoE). Uniquity is pursuing potential best-in-class efficacy and convenient dose optimization across these conditions. By preventing the binding of TSLP to its receptors, solrikitug has potential utility in a wide array of immunology and inflammation diseases. Uniquity is also in the process of identifying bispecific candidates for clinical testing, combining solrikitug with other key inflammatory targets to enhance efficacy and/or broaden the applicable patient population in specific indications.
'Will's leadership, combined with his operational and commercial experience, are the right fit for Uniquity at this stage of the organization's evolution and development,' said Bill Meury, chairman of the Uniquity Bio board of directors. 'The company has tremendous potential, with a seasoned leadership team, an exciting asset in development and a real need for solrikitug in several different indications. As I look ahead to the next phase of Uniquity, I am eager to see how this important work makes a difference for people around the world.'
'Uniquity is in a strong position today — clinically, operationally and financially — and Will's capabilities and expertise will help maximize the success of solrikitug,' said Kiran Reddy, Uniquity Bio board member and senior managing director at Blackstone Life Sciences. 'As we move forward, I'd like to also acknowledge founding CEO Brian Lortie for his leadership and vision, which enabled the company to evolve quickly into an influential biotech advancing a very important medicine in a large market.'
'I am incredibly confident in the Uniquity Bio team and the potentially transformative impact of solrikitug as a highly potent and valuable anti-TSLP therapy,' said Will Kane. 'I look forward to working alongside this talented team to drive both the strategy and execution that meets this important moment for the company. As we prepare for several key milestones, each step forward brings us closer to getting a much-needed medicine into the hands of millions of people suffering from underserved indications.'
ABOUT UNIQUITY BIO
Uniquity Bio is a clinical-stage drug development company built by biopharmaceutical executives with a proven track record and backed by Blackstone Life Sciences. The company is specifically structured to identify and advance therapeutic programs in immunology and inflammation with the scientific rigor and quality standards of a global pharma company, the operational agility of a biotech startup and a laser focus on improving patients' lives. Uniquity Bio is actively advancing its immunology and inflammation pipeline with its lead asset solrikitug, a monoclonal antibody in Phase II trials targeting TSLP. The company anticipates delivering best-in-class efficacy and convenient dose optimization in multiple respiratory and gastrointestinal indications with significant unmet needs. For more information, please visit www.uniquity.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
8 hours ago
- Chicago Tribune
Former Chicago Blackhawks player Patrick Kane sells Near North Side condo for $6.4M
Former Chicago Blackhawks great Patrick Kane, who now skates for the Detroit Red Wings, in late June sold his four-bedroom, 4,776-square-foot condominium on the 25th floor of the luxury Near North Side tower at 9 W. Walton Street in an off-market transaction for $6.4 million. Kane starred as a right winger for the Blackhawks from 2007 until 2023, during that time leading the club to three Stanley Cup finals victories and being selected to nine NHL All-Star Games. Over the years, Kane has owned several residential properties in Chicago and on the North Shore. In the building at 9 W. Walton, Kane paid $6.4625 million in 2019 for his unit. In late June, Kane sold the unit in an off-market deal, according to public records, so no details about are available in listing information. However, in a sign of the softness of the downtown condo market, Kane took a loss on the $6.4 million sale, selling the condo for 1% less than he had paid for it in 2019. At the time Kane purchased the unit, it had 4-1/2 bathrooms, a fireplace and hardwood floors, according to listing information. The buyer of the unit is an opaque land trust whose beneficiary — and thus, the actual buyer of the condo — could not be determined. The trustee for that land trust is Jeffrey Zaluda, a partner in the private client practice at the law firm of Kilpatrick Townsend & Stockton. He did not respond to a request for comment. Kane continues to own at least two other Chicago-area properties. In 2008, he paid $2.06 million for a 33th-floor condo in the Trump International Hotel & Tower. Kane continues to own that unit. He also reportedly paid $5 million in 2022 for a five-bedroom, 5,932-square-foot Greek Revival-style house close to Lake Michigan in Lake Forest. In late March, Kane sold a three-bedroom, 3,102-square-foot unit on the 69th floor of the Trump building for $2.11 million. Kane's now-former condo unit in the building at 9 W. Walton had a $133,427 property tax bill in the 2023 tax year. The building at 9 W. Walton once had been a haven for athletes, but in recent years, athletes there have been doing more selling than buying. Former Chicago Bulls guard Zach LaVine currently has his three-bedroom, 4,500-square-foot condo on the building's 28th floor — which he bought from former Chicago Bears linebacker Khalil Mack — for sale for $6.9 million. Kane's former teammate and onetime fellow Blackhawks star, Jonathan Toews, sold his 29th-floor unit in the building in 2019 for $6.95 million. Also, former Chicago Cubs player Jason Heyward sold a four-bedroom, 5,230-square-foot condo in the building in 2020 for $7.2 million.
Yahoo
a day ago
- Yahoo
Merck & Co., Inc. (MRK) Needs To Move On From Talking About Its Animal Division, Says Jim Cramer
We recently published . Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc. (NYSE:MRK)'s shares have lost 18.3% year-to-date on the back of several factors, such as troubles in China and the expiration of its KEYTRUDA patents. Cramer's previous comments about the firm have praised the firm's deal with Verona, through which it will get access to a chronic pulmonary obstructive disease (COPD) treatment. The acquisition is important as investors have grown concerned about Merck & Co., Inc. (NYSE:MRK)'s drug pipeline and wondered whether future drugs will mimic KEYTRUDA's success. Cramer discussed these factors: 'Well, this GARDASIL, when is it? The Chinese are not really helping them sell, because you would have thought the Chinese would. . .and then you've got the KEYTRUDA, you know the patent cliff coming up. . .it's amazing, but they are talking about their animal division. When you're talking about your animal division you don't have enough [inaudible] to talk.' Later in the day, he commented on Merck & Co., Inc. (NYSE:MRK)'s earnings: 'What do we make of the numbers that we got from Merck this morning? The pharma titan reported what some thought was a mixed quarter. I actually liked it. Small revenue miss, paired with an 11-cent earnings beat. Stock got hit, finishing the day down nearly 2% although it was a lot lower at one point. While we acknowledge the potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Medscape
2 days ago
- Medscape
Treatment Considerations for End-Stage COPD
This transcript has been edited for clarity. Hi, everyone. Dr Chandrasekaran here, and today I'm going to talk about end-stage COPD (chronic obstructive pulmonary disease). We commonly diagnose COPD based off one of three things. One being imaging, showing emphysema or bronchitis; one being pulmonary function tests that can show obstruction; and one being symptom-based. Together, these help us to stage, define, manage, and treat patients with COPD. Once they do reach end-stage COPD, this becomes a healthcare burden associated with increased hospitalizations. We manage these patients by making sure they are on triple-therapy inhalers, including a LAMA (long-acting muscarinic antagonist), LABA (long-acting beta agonist), and inhaled corticosteroids. In addition, we can add theophylline or roflumilast to help decrease hospital readmissions. Chronic azithromycin therapy, 250 mg three times a week, has been shown to decrease shortness of breath and recurrent hospital admissions. Prior to starting this, sensorineural hearing tests along with QTc must be done to make sure that they are not increasing or addition, noninvasive ventilation can help these patients, as they do suffer from sleep-disordered breathing, and help decrease the hypercapnia that these patients face. Long-term oxygen therapy needs to be considered for end-stage COPD, along with lung volume reduction surgery in a handful of patients that do qualify and endobronchial valves in patients who have emphysema and qualify for these mechanisms.
